Skip Navigation

European Heart Journal 1997 18(Supplement C):19-26; doi:10.1093/eurheartj/18.suppl_C.19
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gershlick, A. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gershlick, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European Society of Cardiology

Treating the non-electrical risks of atrial fibrillation

A. H. Gershlick

Department of Academic cardiology, Glenfield Hospital Leicester U.K.

Correspondence: A. H. Gershlick, Department of Academic Cardiology, Glenfield Hospital, Groby Road, Leicester LE3 9QP, U.K.

Atrial fibrillation is a common condition and carries a risk of thromboembolism. There is general acceptance that those patients with atrial fibrillation secondary to valvular (and in particular mitral) heart disease or following valve replacement require anticoagulation. Since patients with non-valvular causes of atrial fibrillation are a more heterogeneous group, the indications for anticoagulation have been less clear. A number of benchmark studies clearly indicate that the risk of stroke can be reduced by up to 70% in those treated with warfarin, but only by a variable 30% with aspirin. Problems with interpretation of the results of these studies relate to the younger age range included and a low recruitment rate, leading to a possible under-estimate of the bleeding risk.

Subgroup analysis provides risk stratification for patients with non-valvular atrial fibrillation so that those with three or more of any of the five following risk factors: congestive heart failure, hypertension, previous stroke, left atrial enlargement or left ventricular hypertrophy, have an 18% chance of new thromboembolic events, whereas this falls to one third of this with only one or two risk factors, and 1% with none. Those with so-called lone atrial fibrillation aged <60 years have a very low incidence of atrial fibrillation and can be considered for aspirin alone. The trials supporting in these statements are presented.

Key Words: Atrial fibrillation • stroke • warfarin • aspirin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
M. Preik, M. Kelm, P. Rosen, D. Tschope, and B. E. Strauer
Additive Effect of Coexistent Type 2 Diabetes and Arterial Hypertension on Endothelial Dysfunction in Resistance Arteries of Human Forearm Vasculature
Angiology, July 1, 2000; 51(7): 545 - 554.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.